Cargando…
Use of GMI‐1271, an E‐selectin antagonist, in healthy subjects and in 2 patients with calf vein thrombosis
BACKGROUND: There is an unmet need for antithrombotic treatments for venous thromboembolic disease that do not increase bleeding risk. Selectins are cell adhesion molecules that augment thrombosis by activating immune cells to initiate the coagulation cascade. GMI‐1271, a potent small‐molecule E‐sel...
Autores principales: | Devata, Sumana, Angelini, Dana E., Blackburn, Susan, Hawley, Angela, Myers, Daniel D., Schaefer, Jordan K., Hemmer, Martina, Magnani, John L., Thackray, Helen M., Wakefield, Thomas W., Sood, Suman L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040550/ https://www.ncbi.nlm.nih.gov/pubmed/32110749 http://dx.doi.org/10.1002/rth2.12279 |
Ejemplares similares
-
Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
por: Muz, Barbara, et al.
Publicado: (2019) -
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271
por: Natoni, A, et al.
Publicado: (2017) -
AML-337: Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy
por: Chang, Kyung Hee, et al.
Publicado: (2020) -
Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia
por: Wun, Ted, et al.
Publicado: (2014) -
Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)